What's on this Page
What is Pertuzumab Trastuzumab Hyaluronidase
Pertuzumab trastuzumab hyaluronidase is a combination product for subcutaneous use.
Both pertuzumab and trastuzumab are monoclonal antibodies and human epidermal growth factor receptor 2 (HER2)/neu-receptor antagonists; these drugs bind to different sites on HER2.
Hyaluronidase-zzxf is an endoglycosidase used to increase the dispersion and absorption of coadministered drugs when administered subcutaneously.
Pertuzumab trastuzumab hyaluronidase is indicated in combination with chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer or as adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence.
It is also indicated in combination with docetaxel for the treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
It has black box warnings for serious cardiotoxicity and pulmonary toxicity and a risk of embryo-fetal death and birth defects if used during pregnancy; use of effective contraception is necessary during and after therapy.
Indications
- breast cancer
For the treatment of HER2-positive breast cancer
Side Effects
- abdominal pain
- abdominal pain
- acute respiratory distress syndrome (ARDS)
- alopecia
- anaphylactoid reactions
- anemia
- anemia
- angioedema
- anorexia
- anorexia
- antibody formation
- arthralgia
- asthenia
- asthenia
- atopic dermatitis
- back pain
- bone pain
- cardiomyopathy
- constipation
- cough
- cough
- diarrhea
- diarrhea
- dizziness
- dysgeusia
- dyspepsia
- dyspnea
- dyspnea
- elevated hepatic enzymes
- elevated hepatic enzymes
- epistaxis
- erythema
- fatigue
- fatigue
- fetal death
- fever
- headache
- heart failure
- hemorrhoids
- hot flashes
- hyperbilirubinemia
- hyperkalemia
- hyperkalemia
- hypernatremia
- hypernatremia
- hyperphosphatemia
- hyperuricemia
- hypoalbuminemia
- hypoglycemia
- hypokalemia
- hypokalemia
- hyponatremia
- hyponatremia
- infection
- infection
- influenza
- infusion-related reactions
- injection site reaction
- insomnia
- lacrimation
- lacrimation
- leukopenia
- leukopenia
- lymphopenia
- lymphopenia
- malaise
- muscle cramps
- musculoskeletal pain
- musculoskeletal pain
- myalgia
- myalgia
- nail discoloration
- nausea
- nausea
- nephrotoxicity
- neutropenia
- neutropenia
- palmar-plantar erythrodysesthesia (hand and foot syndrome)
- palmar-plantar erythrodysesthesia (hand and foot syndrome)
- paresthesias
- paresthesias
- peripheral edema
- peripheral neuropathy
- peripheral neuropathy
- pharyngitis
- pneumonitis
- pruritus
- pulmonary toxicity
- rash
- rash
- renal failure (unspecified)
- rhinorrhea
- stomatitis
- stomatitis
- teratogenesis
- thrombocytopenia
- tumor lysis syndrome (TLS)
- vomiting
- vomiting
- weight loss
- weight loss
- xerophthalmia
- xerophthalmia
- xerosis
- xerosis
Monitoring Parameters
- ejection fraction
- pregnancy testing
- serum creatinine/BUN
- serum electrolytes
- serum uric acid
Contraindications
- breast-feeding
- cardiac arrhythmias
- cardiac disease
- cardiomyopathy
- chronic lung disease (CLD)
- contraception requirements
- ensure correct formulation selection
- geriatric
- heart failure
- hypertension
- infusion-related reactions
- intrauterine fetal death
- myocardial infarction
- pregnancy
- pregnancy testing
- pulmonary toxicity
- reproductive risk
- tumor lysis syndrome (TLS)
- ventricular dysfunction
Interactions
No information is available regarding drug interactions associated with Pertuzumab Trastuzumab Hyaluronidase